Analyst Price Target is $5.33
▲ +417.80% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Clearside Biomedical in the last 3 months. The average price target is $5.33, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 417.80% upside from the last price of $1.03.
Current Consensus is
Buy
The current consensus among 6 polled investment analysts is to buy stock in Clearside Biomedical. This Buy consensus rating has held steady for over two years.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Read More